<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0136304</article-id>
<article-id pub-id-type="publisher-id">PONE-D-15-15788</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Prostaglandin E2 Receptor EP4 Regulates Obesity-Related Inflammation and Insulin Sensitivity</article-title>
<alt-title alt-title-type="running-head">EP4 Signaling Ameliorates Adipose Tissue Inflammation</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yasui</surname>
<given-names>Mika</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tamura</surname>
<given-names>Yukinori</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Minami</surname>
<given-names>Manabu</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="cor001" ref-type="corresp">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Higuchi</surname>
<given-names>Sei</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Fujikawa</surname>
<given-names>Risako</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ikedo</surname>
<given-names>Taichi</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Nagata</surname>
<given-names>Manabu</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Arai</surname>
<given-names>Hidenori</given-names>
</name>
<xref rid="aff004" ref-type="aff"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Murayama</surname>
<given-names>Toshinori</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Yokode</surname>
<given-names>Masayuki</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Clinical Innovative Medicine, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Physiology and Regenerative Medicine, Kinki University Faculty of Medicine, Osakasayama, Osaka, Japan</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>National Center for Geriatrics and Gerontology, Obu, Aichi, Japan</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Maeda</surname>
<given-names>Norikazu</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Graduate School of Medicine, Osaka University, JAPAN</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: MM. Performed the experiments: M. Yasui YT. Analyzed the data: M. Yasui YT MM. Contributed reagents/materials/analysis tools: SH RF TI MN. Wrote the paper: M. Yasui MM. Revised the article critically: HA TM M. Yokode.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">mminami@kuhp.kyoto-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>8</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>10</volume>
<issue>8</issue>
<elocation-id>e0136304</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>4</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>8</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Yasui et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0136304" xlink:type="simple"/>
<abstract>
<p>With increasing body weight, macrophages accumulate in adipose tissue. There, activated macrophages secrete numerous proinflammatory cytokines and chemokines, giving rise to chronic inflammation and insulin resistance. Prostaglandin E<sub>2</sub> suppresses macrophage activation via EP4; however, the role of EP4 signaling in insulin resistance and type 2 diabetes mellitus remains unknown. In this study, we treated <italic>db/db</italic> mice with an EP4-selective agonist, ONO-AE1-329, for 4 weeks to explore the role of EP4 signaling in obesity-related inflammation <italic>in vivo</italic>. Administration of the EP4 agonist did not affect body weight gain or food intake; however, in the EP4 agonist–treated group, glucose tolerance and insulin resistance were significantly improved over that of the vehicle–treated group. Additionally, administration of the EP4 agonist inhibited the accumulation of F4/80-positive macrophages and the formation of crown-like structures in white adipose tissue, and the adipocytes were significantly smaller. The treatment of the EP4 agonist increased the number of anti-inflammatory M2 macrophages, and in the stromal vascular fraction of white adipose tissue, which includes macrophages, it markedly decreased the levels of proinflammatory cytokines and chemokines. Further, EP4 activation increased the expression of adiponectin and peroxidase proliferator–activated receptors in white adipose tissue. Next, we examined <italic>in vitro</italic> M1/M2 polarization assay to investigate the impact of EP4 signaling on determining the functional phenotypes of macrophages. Treatment with EP4 agonist enhanced M2 polarization in wild-type peritoneal macrophages, whereas EP4-deficient macrophages were less susceptible to M2 polarization. Notably, antagonizing peroxidase proliferator–activated receptor δ activity suppressed EP4 signaling-mediated shift toward M2 macrophage polarization. Thus, our results demonstrate that EP4 signaling plays a critical role in obesity-related adipose tissue inflammation and insulin resistance by regulating macrophage recruitment and polarization. The activation of EP4 signaling holds promise for treating obesity and type 2 diabetes mellitus.</p>
</abstract>
<funding-group>
<funding-statement>Funding for this work was provided by the the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Numbers 20890111, 23590361, and 26460338 (to MM), 15K08230 (to MY): <ext-link ext-link-type="uri" xlink:href="https://www.jsps.go.jp/j-grantsinaid/index.html" xlink:type="simple">https://www.jsps.go.jp/j-grantsinaid/index.html</ext-link>, the Suzuken Memorial Foundation (to MM): <ext-link ext-link-type="uri" xlink:href="http://www.suzukenzaidan.or.jp" xlink:type="simple">http://www.suzukenzaidan.or.jp</ext-link>, the Metabolic Syndrome Research Forum Fund (to MM), the Takeda Science Foundation (to MM): <ext-link ext-link-type="uri" xlink:href="http://www.takeda-sci.or.jp" xlink:type="simple">http://www.takeda-sci.or.jp</ext-link>, and the SENSHIN Medical Research Foundation (to MM): <ext-link ext-link-type="uri" xlink:href="http://www.mt-pharma.co.jp/zaidan/" xlink:type="simple">http://www.mt-pharma.co.jp/zaidan/</ext-link>.</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="1"/>
<page-count count="16"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Obesity predisposes to several metabolic diseases such as insulin resistance, type 2 diabetes mellitus (T2DM), and arteriosclerosis. Developing novel approaches for the prevention and treatment of T2DM is a matter of great importance.</p>
<p>Excess calorie intake contributes to increased body weight, which is associated with larger adipocytes, preadipocyte differentiation, and abnormal adipokine secretion [<xref rid="pone.0136304.ref001" ref-type="bibr">1</xref>]. Hypertrophic adipocytes secrete monocyte chemotactic protein-1 (MCP-1), which promotes macrophage infiltration into obese adipose tissue, thus inducing chronic, low-grade inflammation [<xref rid="pone.0136304.ref002" ref-type="bibr">2</xref>]. White adipose tissue (WAT) is an important site for obesity-related chronic inflammation where adipose tissue macrophages (ATMs) produce proinflammatory cytokines and chemokines, such as tumor necrosis factor alpha (TNFα) and MCP-1 [<xref rid="pone.0136304.ref003" ref-type="bibr">3</xref>]. The activation of inflammatory signaling can trigger whole-body insulin resistance by directly influencing insulin signaling [<xref rid="pone.0136304.ref004" ref-type="bibr">4</xref>–<xref rid="pone.0136304.ref006" ref-type="bibr">6</xref>].</p>
<p>There are two major phenotypes for macrophages, M1 (classically activated) and M2 (alternatively activated) [<xref rid="pone.0136304.ref007" ref-type="bibr">7</xref>]. M1 macrophages produce proinflammatory cytokines and are induced by Th1 cell–derived interferon (IFN) γ and lipopolysaccharide (LPS). By contrast, M2 macrophages reduce inflammatory responses by producing anti-inflammatory factors, such as interleukin (IL)-10 and transforming growth factor (TGF)-β [<xref rid="pone.0136304.ref007" ref-type="bibr">7</xref>], and mainly reside in lean adipose tissue. When mice on a high-fat diet become obese, M1 macrophages accumulate in the adipose tissue, resulting in a shift toward M1 polarity, suggesting that the M1/M2 polarization of ATMs plays a key role in insulin resistance and T2DM [<xref rid="pone.0136304.ref008" ref-type="bibr">8</xref>].</p>
<p>Prostanoids, comprised of prostaglandin and thromboxane, are bioactive compounds synthesized in response to various stimuli and are crucial for maintaining tissue homeostasis and inflammation [<xref rid="pone.0136304.ref009" ref-type="bibr">9</xref>]. Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) is one of the major prostanoids generated by the metabolism of arachidonic acid by cyclooxygenase (COX) and PGE synthases [<xref rid="pone.0136304.ref010" ref-type="bibr">10</xref>]. It has four G protein–coupled receptors: EP1 through EP4 [<xref rid="pone.0136304.ref011" ref-type="bibr">11</xref>]. PGE<sub>2</sub> suppresses the production of proinflammatory cytokines and chemokines via EP4 in LPS–treated human and murine macrophages [<xref rid="pone.0136304.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0136304.ref013" ref-type="bibr">13</xref>]. In fact, EP4 activation suppresses chronic inflammation <italic>in vivo</italic> by mitigating macrophage activation during afflictions such as inflammatory bowel disease [<xref rid="pone.0136304.ref014" ref-type="bibr">14</xref>], ischemia-reperfusion injury [<xref rid="pone.0136304.ref015" ref-type="bibr">15</xref>], atherosclerosis [<xref rid="pone.0136304.ref016" ref-type="bibr">16</xref>], allograft rejection after cardiac transplantation [<xref rid="pone.0136304.ref017" ref-type="bibr">17</xref>], and abdominal aortic aneurysm [<xref rid="pone.0136304.ref018" ref-type="bibr">18</xref>]. In addition, EP4 signaling suppresses adipocyte differentiation [<xref rid="pone.0136304.ref019" ref-type="bibr">19</xref>] and protects against the diabetogenic toxicity of streptozotocin in mice [<xref rid="pone.0136304.ref020" ref-type="bibr">20</xref>]. PGE<sub>2</sub> mediates, at least partially, the biological effects of adiponectin (a crucial anti-inflammatory and anti-atherosclerotic molecule including suppression of adipocyte differentiation [<xref rid="pone.0136304.ref021" ref-type="bibr">21</xref>] and inhibition of ischemia-reperfusion injury [<xref rid="pone.0136304.ref022" ref-type="bibr">22</xref>].</p>
<p>These findings imply important roles for EP4 signaling <italic>in vivo</italic> in obesity-related chronic inflammation and in the subsequent increase of insulin resistance. In this study, we pharmacologically activated the EP4 receptor in <italic>db/db</italic> mice to investigate the pathophysiological role of EP4 signaling in obesity and T2DM.</p>
</sec>
<sec id="sec002" sec-type="results">
<title>Results</title>
<sec id="sec003">
<title>Treatment with an EP4-selective agonist significantly improves glucose tolerance and insulin resistance in obese mice</title>
<p>To determine the role of EP4 signaling in obesity-related inflammation <italic>in vivo</italic>, we administered the EP4-selective agonist ONO-AE1-329 or vehicle for 4 weeks to <italic>db/db</italic> mice. The dosage of the EP4 agonist was determined in accordance with previous reports using animal models of inflammation [<xref rid="pone.0136304.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0136304.ref024" ref-type="bibr">24</xref>]. ONO-AE1-329 treatment did not affect body weight gain (<xref rid="pone.0136304.g001" ref-type="fig">Fig 1A</xref>) or food intake (<xref rid="pone.0136304.g001" ref-type="fig">Fig 1B</xref>). There was no significant difference in the plasma levels of total cholesterol, triglyceride, or hemoglobin A1C between the two groups (<xref rid="pone.0136304.t001" ref-type="table">Table 1</xref>). Additionally, liver weight and epididymal WAT did not differ significantly (<xref rid="pone.0136304.t001" ref-type="table">Table 1</xref>). Despite similar metabolic characteristics, treatment with the EP4 agonist markedly improved glucose tolerance (<xref rid="pone.0136304.g001" ref-type="fig">Fig 1C</xref>). In addition, the insulin tolerance test indicated that the EP4 agonist increased insulin sensitivity (<xref rid="pone.0136304.g001" ref-type="fig">Fig 1D</xref>). Thus, EP4 activation ameliorated obesity-induced abnormal glucose tolerance and insulin resistance.</p>
<fig id="pone.0136304.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0136304.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Effects of EP4 activation on glucose tolerance and insulin resistance.</title>
<p>Seven-week-old male <italic>db/db</italic> mice subcutaneously received either the EP4-selective agonist ONO-AE1-329 (0.3 mg/kg) or vehicle twice a day for 4 weeks. (A) Change in body weight during the study period (n = 8 each). (B) Amount of food intake (n = 8 each). (C) Results of glucose tolerance test: left, time-course of blood glucose levels; right, area under curve (AUC) (n = 7–8 each). (D) Results of insulin tolerance test: left, time-course changes of blood glucose levels; right, the inverse AUC (n = 13 each). All values are mean ± SEM. * p&lt;0.05; ♯ p&lt;0.01 vs. vehicle.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0136304.g001" position="float" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0136304.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0136304.t001</object-id>
<label>Table 1</label> <caption><title>Effects of EP4 agonist on metabolic parameters.</title></caption>
<alternatives>
<graphic id="pone.0136304.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0136304.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Measurement</th>
<th align="left" rowspan="1" colspan="1">Vehicle</th>
<th align="left" rowspan="1" colspan="1">ONO-AE1-329</th>
<th align="left" rowspan="1" colspan="1">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">T-Cho (mg/dl)</td>
<td align="left" rowspan="1" colspan="1">117.35 ± 21.71</td>
<td align="left" rowspan="1" colspan="1">115.51 ± 12.16</td>
<td align="left" rowspan="1" colspan="1">N.S.</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">TG (mg/dl)</td>
<td align="left" rowspan="1" colspan="1">141.27 ± 37.18</td>
<td align="left" rowspan="1" colspan="1">153.06 ± 33.89</td>
<td align="left" rowspan="1" colspan="1">N.S.</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HbA1c (%)</td>
<td align="left" rowspan="1" colspan="1">6.28 ± 0.42</td>
<td align="left" rowspan="1" colspan="1">6.05 ± 0.22</td>
<td align="left" rowspan="1" colspan="1">N.S.</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Liver (g)</td>
<td align="left" rowspan="1" colspan="1">2.49 ± 0.25</td>
<td align="left" rowspan="1" colspan="1">2.43 ± 0.17</td>
<td align="left" rowspan="1" colspan="1">N.S.</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Epididymal WAT (g)</td>
<td align="left" rowspan="1" colspan="1">2.35 ± 0.09</td>
<td align="left" rowspan="1" colspan="1">2.30 ± 0.15</td>
<td align="left" rowspan="1" colspan="1">N.S.</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Values are mean ± SEM (n = 3–8 each). T-Cho, total cholesterol; TG, triglyceride; HbA1c, Hemoglobin A1c; WAT, white adipose tissue.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec004">
<title>EP4 signaling inhibits macrophage accumulation in crown-like structures and inflammatory activation in obese adipose tissues</title>
<p>Accumulation of macrophages in adipose tissues elicits inflammation, which in turn, causes local and systemic insulin resistance and T2DM [<xref rid="pone.0136304.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0136304.ref025" ref-type="bibr">25</xref>]. Because several lines of evidence indicate that EP4 signaling in macrophages has anti-inflammatory effects, we next investigated the impact of EP4 activation on inflammatory burden in obese adipose tissue. Immunohistochemistry revealed that the accumulation of F4/80-positive macrophages in crown-like structures (CLSs) within epididymal WAT was markedly decreased in the EP4 agonist–treated group (<xref rid="pone.0136304.g002" ref-type="fig">Fig 2A and 2B</xref>). Accordingly, the sizes of adipocytes in the EP4 agonist–treated group were significantly smaller compared to that of the vehicle–treated group (<xref rid="pone.0136304.g002" ref-type="fig">Fig 2A and 2C</xref>). Though there was no significant difference in the mRNA expression of <italic>Mcp-1</italic> in WAT (<xref rid="pone.0136304.s002" ref-type="supplementary-material">S1A Fig</xref>), there was a trend towards decreased secretion of MCP-1 protein in the EP4 agonist–treated mice (p = 0.054) (<xref rid="pone.0136304.s002" ref-type="supplementary-material">S1B Fig</xref>).</p>
<fig id="pone.0136304.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0136304.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Adipose tissue morphology.</title>
<p>(A) Representative images of epididymal adipose tissue stained with anti-F4/80 antibody (upper panel; the arrows indicate F4/80-positive cells) and H&amp;E (lower panel) in <italic>db/db</italic> mice administered EP4 agonist (right column) or vehicle (left column). Scale bars: 100 μm. (B) Percent of F4/80<sup>+</sup> CLS areas in mouse epididymal adipose tissue (n = 7 each). (C) Quantification of adipocyte size (n = 7 each). All values are mean ± SEM. ♯ p&lt;0.01 vs. vehicle. CLS, crown-like structures.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0136304.g002" position="float" xlink:type="simple"/>
</fig>
<p>To investigate the effect of EP4 activation on ATM activation, we isolated stromal vascular fraction (SVF) from epididymal WAT, which contains inflammatory cells including ATMs, and then measured the mRNA levels of proinflammatory cytokines and chemokines. The EP4 agonist–treated group had decreased expression of a number of genes encoding proinflammatory cytokines and chemokines such as <italic>Tnfα</italic>, <italic>Il-6</italic>, <italic>Mcp-1</italic>, and interferon gamma–induced protein 10 (<italic>Ip-10</italic>) (<xref rid="pone.0136304.g003" ref-type="fig">Fig 3</xref>). These results indicate that activation of EP4 signaling has potent anti-inflammatory effects in ATMs.</p>
<fig id="pone.0136304.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0136304.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Cytokine and chemokine gene expression in SVF.</title>
<p>Relative expression of <italic>Tnfα</italic>, <italic>Il-6</italic>, <italic>Mcp-1</italic>, and <italic>Ip-10</italic> mRNA in SVF isolated from <italic>db/db</italic> mice administered EP4 agonist (black bar) or vehicle (white bar). All values are mean ± SEM (n = 3 each). * p&lt;0.05; ♯ p&lt;0.01 vs. vehicle. SVF, stromal vascular fraction; Tnfα, tumor necrosis factor α; Il-6, interleukin-6; Mcp-1, monocyte chemotactic protein-1; Ip-10, interferon gamma–induced protein 10.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0136304.g003" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec005">
<title>EP4 signaling enhances the polarization of adipose tissue macrophages toward the M2 phenotype</title>
<p>ATMs are comprised of two distinct subsets: the classically activated, proinflammatory M1 macrophages and the alternatively activated, anti-inflammatory M2 macrophages. The total number of infiltrated macrophages and the M1/M2 balance of those macrophages determine the features of chronic inflammatory diseases such as obesity and T2DM [<xref rid="pone.0136304.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0136304.ref026" ref-type="bibr">26</xref>]. To evaluate the polarization of ATMs, we performed quantitative PCR on total mRNA from epididymal WAT. The expression of genes encoding the M2 markers mannose receptor (<italic>MR</italic>) and <italic>Cd163</italic> was increased in the EP4 agonist–treated group, whereas the gene encoding the M1 marker <italic>Cd11c</italic> was not significantly different between the two groups (<xref rid="pone.0136304.g004" ref-type="fig">Fig 4A</xref>). Peroxidase proliferator–activated receptor (PPAR) δ and PPARγ are key factors in polarizing macrophages to M2 status [<xref rid="pone.0136304.ref026" ref-type="bibr">26</xref>–<xref rid="pone.0136304.ref029" ref-type="bibr">29</xref>]. In our study, the expression of these genes in WAT was significantly increased by consecutive administration of EP4 agonist (<xref rid="pone.0136304.s003" ref-type="supplementary-material">S2 Fig</xref>). Accordingly, immunofluorescence of epididymal WAT demonstrated that F4/80<sup>+</sup> CD163<sup>+</sup> M2 macrophages, not F4/80<sup>+</sup> CD11c<sup>+</sup> M1 macrophages, were more abundant in the EP4 agonist–treated group (<xref rid="pone.0136304.g004" ref-type="fig">Fig 4B</xref>).</p>
<fig id="pone.0136304.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0136304.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Administration of EP4 agonist alters adipose tissue macrophage polarization.</title>
<p>(A) Relative expression of marker genes for M1 (<italic>Cd11c</italic>) and M2 (<italic>MR</italic>, <italic>Cd163</italic>) macrophages in epididymal fat tissues from <italic>db/db</italic> mice administered EP4 agonist (black bar) or vehicle (white bar). All values are mean ± SEM (n = 4–5 each). ♯ p&lt;0.01 vs. vehicle. (B) Epididymal adipose tissues of EP4 agonist–or vehicle–treated <italic>db/db</italic> mice were double stained with anti-F4/80 (green), and anti-CD11c (red, upper panel) or anti-CD163 (red, lower panel) antibodies. Arrows indicate double-positive cells. Scale bar: 100 μm. MR, Mannose Receptor.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0136304.g004" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec006">
<title>Impact of EP4 signaling on the balance of adipokine secretion</title>
<p>Adipokines, including adiponectin, are produced and secreted from fat cells in adipose tissues and regulate systemic insulin sensitivity [<xref rid="pone.0136304.ref030" ref-type="bibr">30</xref>]. The nuclear receptors PPARα and PPARγ regulate the expression of adiponectin [<xref rid="pone.0136304.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0136304.ref032" ref-type="bibr">32</xref>]. Adiponectin, in turn, suppresses macrophage infiltration into adipose tissue and promotes alternative M2 macrophage activation [<xref rid="pone.0136304.ref033" ref-type="bibr">33</xref>,<xref rid="pone.0136304.ref034" ref-type="bibr">34</xref>]. In the EP4 agonist–treated group, the expression levels of <italic>PPARα</italic> and <italic>PPARγ</italic> in WAT were significantly increased, along with production of adiponectin (<xref rid="pone.0136304.s003" ref-type="supplementary-material">S2 Fig</xref> and <xref rid="pone.0136304.g005" ref-type="fig">Fig 5A</xref>). Consequently, though not statistically significant (p = 0.079), the plasma levels of adiponectin exhibited a possible trend toward significance in the EP4 agonist–treated group (<xref rid="pone.0136304.g005" ref-type="fig">Fig 5B</xref>), suggesting that polarization of ATMs toward the anti-inflammatory M2 phenotype balanced adipokine secretion and improved insulin sensitivity in obese mice.</p>
<fig id="pone.0136304.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0136304.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Impact of EP4 activation on adiponectin expression.</title>
<p>Relative adiponectin mRNA levels in epididymal fat tissue (A) and plasma adiponectin concentrations (B) were measured in EP4 agonist–(black bar) or vehicle–treated (white bar) <italic>db/db</italic> mice. All values are mean ± SEM (n = 6 each). ♯ p&lt;0.01 vs. vehicle.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0136304.g005" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec007">
<title>EP4 signaling promotes M2 macrophage polarization in isolated murine macrophages</title>
<p>To investigate whether EP4 signaling directly influences macrophage polarization, we freshly isolated peritoneal macrophages from WT mice and performed <italic>in vitro</italic> M1/M2 polarization assays as previously described [<xref rid="pone.0136304.ref035" ref-type="bibr">35</xref>]. The expression of marker genes for M1 and M2 macrophages was assayed by quantitative PCR. In WT macrophages, LPS stimulation induced the mRNA expression of M1 genes, such as <italic>Tnfα</italic> and <italic>Il-6</italic>, whereas adding the EP4 agonist to the LPS mixture decreased the mRNA expression of those genes (<xref rid="pone.0136304.g006" ref-type="fig">Fig 6A</xref>). On the other hand, co-stimulation with IL-4 and IL-13 enabled peritoneal macrophages to polarize to M2 status (<xref rid="pone.0136304.g006" ref-type="fig">Fig 6B</xref>). Notably, treatment with the EP4 agonist with IL-4 and IL-13 further increased the mRNA expression of M2 genes, including <italic>MR</italic> and <italic>Cd163</italic> (<xref rid="pone.0136304.g006" ref-type="fig">Fig 6B</xref>).</p>
<fig id="pone.0136304.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0136304.g006</object-id>
<label>Fig 6</label>
<caption>
<title>EP4 signaling is important in macrophage polarization.</title>
<p><italic>In vitro</italic> M1/M2 polarization assays were performed using peritoneal macrophages freshly isolated from 12 to 15-week-old male WT (white bar) or EP4-deficient mice (black bar). To determine M1 or M2 polarization, cells were incubated with 1 μg/ml of LPS (A, C), or with 20 ng/ml of IL-4 and IL-13 (B, D), as well as with 1 μM of EP4 agonist or vehicle. Eight hours later, marker gene expression for M1 (<italic>Tnfα</italic> and <italic>Il-6</italic>) (A, C) or M2 (<italic>MR</italic> and <italic>Cd163</italic>) (B, D) polarity was measured. To clarify the role of PPARs in EP4-dependent M2 polarization, peritoneal macrophages were pretreated with GSK3787 (PPARδ antagonist) (E), GW9662 (PPARγ antagonist) (F) or vehicle prior to the administration of IL-4/IL-13 and the EP4 agonist. Results are expressed as the fold induction of M2 genes compared with unantagonized, vehicle-treated cells. All values are mean ± SEM (n = 6 each). * p&lt;0.05; ♯ p&lt;0.01. LPS, lipopolysaccharide.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0136304.g006" position="float" xlink:type="simple"/>
</fig>
<p>To investigate the impact of EP4 deletion on macrophage polarization, we collected peritoneal macrophages from EP4 knockout mice and estimated M1/M2 polarization. EP4 deficiency resulted in increased susceptibility to M1 and less susceptibility to M2 macrophage polarization (<xref rid="pone.0136304.g006" ref-type="fig">Fig 6C and 6D</xref>), suggesting that EP4 signaling may act directly on macrophage polarization. These results indicate that the activation of EP4 signaling mitigates chronic inflammation in adipose tissue by regulating ATM activation and polarization.</p>
<p>Next, we examined the downstream of EP4 signaling that enhanced M2 polarization. It is well known that the activation of PPARs is one of the keys in polarizing macrophages to M2 status [<xref rid="pone.0136304.ref026" ref-type="bibr">26</xref>–<xref rid="pone.0136304.ref029" ref-type="bibr">29</xref>]. When we added GSK3787, PPARδ selective antagonist, prior to IL-4/IL-13 in <italic>in vitro</italic> M1/M2 polarization assays, the EP4-dependent increase of <italic>Cd163</italic> or <italic>MR</italic> gene expression markedly inhibited (<xref rid="pone.0136304.g006" ref-type="fig">Fig 6E</xref>). On the other hand, pretreatment of GW9662, PPARγ antagonist, suppressed the enhanced expression of <italic>Cd163</italic> but not <italic>MR</italic> by EP4 agonist (<xref rid="pone.0136304.g006" ref-type="fig">Fig 6F</xref>). These results suggest that PPARs, especially PPARδ, might coordinate EP4 signaling in macrophage polarization toward an M2-like phenotype.</p>
</sec>
</sec>
<sec id="sec008" sec-type="conclusions">
<title>Discussion</title>
<p>Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) has been shown to exert energy and metabolic homeostasis: for instance, PGE<sub>2</sub> regulates lipolysis and increases leptin release in primary culture of rodent and human adipose tissues [<xref rid="pone.0136304.ref036" ref-type="bibr">36</xref>–<xref rid="pone.0136304.ref038" ref-type="bibr">38</xref>], while EP3-deficient mice displayed increased feeding and body weight despite elevated plasma leptin levels [<xref rid="pone.0136304.ref039" ref-type="bibr">39</xref>]. In addition, a previous report demonstrated that intracerebroventricular administration of PGE<sub>2</sub> or EP4 agonist decreased food intake in fasted mice [<xref rid="pone.0136304.ref040" ref-type="bibr">40</xref>]. In this study, however, administration of EP4 selective agonist did not affect body weight gain, food intake or blood lipid profile. It may be partially because that in our study, we used leptin receptor-deficient <italic>db/db</italic> mice fed with normal chow <italic>ad libitum</italic>, and administered EP4 agonist peripherally. Besides, in WAT, other EP receptors including EP3 express and activate intracellular signal transduction pathways differing from EP4.</p>
<p>EP4 activation is pivotally involved in ameliorating chronic inflammatory diseases [<xref rid="pone.0136304.ref014" ref-type="bibr">14</xref>–<xref rid="pone.0136304.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0136304.ref041" ref-type="bibr">41</xref>]. Macrophages, known to have abundant EP4 expression [<xref rid="pone.0136304.ref012" ref-type="bibr">12</xref>], accumulate in hypertrophied adipose tissues and play crucial roles in the pathogenesis of insulin resistance and T2DM by promoting inflammation. Therefore, we examined the impact of EP4 signaling on obesity-related adipose tissue inflammation <italic>in vivo</italic> using an animal model of obesity and T2DM.</p>
<p>Obesity is generally caused by the combination of excess calorie intake, insufficient physical activity, and genetic predisposition. Obese adipose tissue is characterized by hypertrophied adipocytes, increased production of proinflammatory cytokines and chemokines, and infiltration by immune cells, including macrophages [<xref rid="pone.0136304.ref042" ref-type="bibr">42</xref>]. Though there was no significant difference in the weight of epididymal adipose tissue in our study, the adipocytes were less hypertrophied in the EP4 agonist–treated group. Hypertrophied adipocytes secrete MCP-1, leading to the recruitment of circulating monocytes and subsequent infiltration by macrophages into adipose tissues. Infiltrated ATMs, in turn, secrete MCP-1 and other proinflammatory cytokines and chemokines; consequently a number of ATMs accumulate in adipose tissues, causing chronic inflammation in WAT [<xref rid="pone.0136304.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0136304.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0136304.ref025" ref-type="bibr">25</xref>]. PGE<sub>2</sub>-EP4 signaling suppresses MCP-1 expression in a variety of inflammatory settings [<xref rid="pone.0136304.ref043" ref-type="bibr">43</xref>,<xref rid="pone.0136304.ref044" ref-type="bibr">44</xref>]. Our data demonstrated that consecutive administration of EP4 receptor–agonist into obese mice significantly decreased MCP-1 production in SVF, a fraction containing macrophages but not adipocytes, suggesting that EP4 signaling mainly affects ATMs and inhibits the deleterious consequences of local chemokine production and macrophage infiltration.</p>
<p>Obesity causes a shift in macrophage polarity from the anti-inflammatory M2 to the pro-inflammatory M1 state, facilitating insulin resistance [<xref rid="pone.0136304.ref008" ref-type="bibr">8</xref>]. Using mice with mutations in key proteins of the inflammatory process, it has been demonstrated that an increase in M2 ATMs ameliorates obesity-related impaired glucose metabolism. In one example, mice lacking Tribbles homolog 1 (<italic>Trib1</italic>, which encodes an adaptor protein involved in proteasome-mediated protein degradation) in hematopoietic cells develop glucose intolerance and insulin resistance on a high-fat diet. They have a severely reduced number of M2 ATMs, but no change in M1 ATMs [<xref rid="pone.0136304.ref045" ref-type="bibr">45</xref>]. Hematopoietic deletion of COX-1, a major PGE<sub>2</sub>-producing enzyme, was also associated with metabolic disorders and decreased counts of M2 ATMs in diet-induced obese mice, with M1 counts remaining the same [<xref rid="pone.0136304.ref046" ref-type="bibr">46</xref>]. How M2 ATMs contribute to the amelioration of glucose tolerance and insulin resistance is not fully understood; however, a number of previous reports indicated that M2 macrophages reside in adipose tissues have crucial roles in maintaining normal glucose homeostasis [<xref rid="pone.0136304.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0136304.ref047" ref-type="bibr">47</xref>,<xref rid="pone.0136304.ref048" ref-type="bibr">48</xref>]. Polarized M2 ATMs secrete anti-inflammatory cytokines such as IL-10, improving insulin-stimulated glucose uptake in TNF<italic>α</italic>–treated 3T3-L1 adipocytes [<xref rid="pone.0136304.ref008" ref-type="bibr">8</xref>]. In addition to secreting cytokine or regulating adipokine production, some of M2 ATMs can store large amount of iron: loss of these alternatively activated macrophages may cause abnormal accumulation of iron in adipocytes and enhance iron-induced lipid peroxidation and oxidative stress, which consequently deteriorate adipocyte insulin sensitivity [<xref rid="pone.0136304.ref049" ref-type="bibr">49</xref>]. Besides, M2 ATMs are capable of producing catecholamines such as norepinephrine, activating β3 adrenergic receptor on adipocytes: β3 adrenergic receptor signaling in WAT is pivotally involved in metabolic homeostasis through regulating lipolysis and mitochondrial functions [<xref rid="pone.0136304.ref050" ref-type="bibr">50</xref>,<xref rid="pone.0136304.ref051" ref-type="bibr">51</xref>].</p>
<p>Accordingly, we observed that the activation of EP4 signaling increased the number of M2 macrophages and led to a phonotypic switch toward M2 status in obese adipose tissue. Notably, in our study, EP4 signaling pivotally participated in M1/M2 differentiation <italic>in vitro</italic>, and in EP4 agonist–treated mice, the gene expression of <italic>PPARδ</italic> and <italic>PPARγ</italic> in WAT were significantly elevated. PPARδ is induced in response to adipocyte-derived Th2 cytokines, such as IL-4 and IL-13, and facilitates adipocyte differentiation, as well as the recruitment of M2 macrophages into adipose tissue and the liver [<xref rid="pone.0136304.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0136304.ref028" ref-type="bibr">28</xref>]. PPARγ is necessary for the alternative activation of ATMs [<xref rid="pone.0136304.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0136304.ref029" ref-type="bibr">29</xref>]. Thus, our data suggest that EP4 activation regulates macrophage accumulation in obese adipose tissue, as well as differentiation and polarization toward M2 phenotypes, resulting in the suppression of adipose tissue inflammation.</p>
<p>Adipose tissues secrete various adipokines, and the plasma adipokine levels can be an indicator of systemic inflammation and insulin resistance. Adiponectin is one of the major adipokines, exhibiting anti-diabetic, anti-atherosclerotic, and anti-inflammatory properties [<xref rid="pone.0136304.ref052" ref-type="bibr">52</xref>]. The activation of PGE<sub>2</sub>-EP4 signaling is crucial for the protective function of adiponectin [<xref rid="pone.0136304.ref022" ref-type="bibr">22</xref>]. In addition, adiponectin promotes the alternative activation of macrophages and polarization toward the anti-inflammatory M2 phenotype [<xref rid="pone.0136304.ref034" ref-type="bibr">34</xref>,<xref rid="pone.0136304.ref053" ref-type="bibr">53</xref>]. Our study indicates that consecutive EP4 activation induces local adiponectin production in WAT, which in turn, might contribute to the phenotypic shift of ATMs into M2 status and suppression of adipose tissue inflammation. In contrast to enhanced adiponectin mRNA levels in WAT, we observed no statistically significant change in the plasma levels of total adiponectin in EP4 agonist–treated group; yet some previous works demonstrated that insulin sensitivity does not always correlate with the plasma total adiponectin levels, because adiponectin circulates in the blood in multimeric forms with different metabolic activities [<xref rid="pone.0136304.ref054" ref-type="bibr">54</xref>,<xref rid="pone.0136304.ref055" ref-type="bibr">55</xref>].</p>
<p>Defining the precise mechanisms by which EP4 activation enhances M2 polarization is beyond the scope of the current study; however, as discussed above, successive treatment of obese mice with EP4-selective agonist enhances <italic>PPARγ</italic>, <italic>PPARδ</italic>, and adiponectin expression, which may explain the polarity shift of accumulated macrophages, at least partially. EP4 is coupled to Gs, which stimulates adenylate cyclase, and thus, increases intracellular cAMP levels, consequently activating protein kinase A and cAMP response element binding protein (CREB) [<xref rid="pone.0136304.ref056" ref-type="bibr">56</xref>]. In differentiated 3T3-L1 adipocytes, adiponectin expression is mediated through cAMP–CREB–PPARγ pathways [<xref rid="pone.0136304.ref057" ref-type="bibr">57</xref>], but it remains controversial whether PGE<sub>2</sub> or EP4 signaling directly acts on the expression of these genes via a cAMP-dependent pathway. Unlike other EP receptors coupled with Gs, EP4 has a long cytoplasmic tail, where the receptor interacts with a novel protein designated EP4 receptor–associated protein (EPRAP) [<xref rid="pone.0136304.ref012" ref-type="bibr">12</xref>]. Because EPRAP exerts an anti-inflammatory effect in LPS-stimulated macrophages <italic>in vitro</italic> [<xref rid="pone.0136304.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0136304.ref013" ref-type="bibr">13</xref>], EPRAP may also contribute to the suppression of obesity-related inflammation.</p>
<p>In this study, we focused on the impact of EP4 signaling in adipose tissues on macrophage activation and polarization. PGE<sub>2</sub> regulates the profibrotic and proinflammatory activation of pancreatic stellate cells via EP4 and protects β-cells from apoptosis [<xref rid="pone.0136304.ref058" ref-type="bibr">58</xref>,<xref rid="pone.0136304.ref059" ref-type="bibr">59</xref>]. Other than adipose tissues, macrophages also infiltrate into the liver and the skeletal muscle in obese subjects, and the polarity appears to be shifted towards M1 status, which has a strong association with dysfunction of these organs and with insulin resistance [<xref rid="pone.0136304.ref027" ref-type="bibr">27</xref>,<xref rid="pone.0136304.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0136304.ref060" ref-type="bibr">60</xref>]. Clarifying the roles of EP4 signaling in macrophage activation and phenotypic switching within these organs could be important for understanding the novel pathophysiological mechanisms of insulin resistance and T2DM.</p>
<p>In summary, administration of an EP4-selective agonist improved insulin sensitivity and glucose tolerance in obese mice. Treatment with EP4 agonist inhibited the accumulation of macrophages and decreased CLS formation, consequently attenuating the expression of proinflammatory cytokines and chemokines, and enhancing adiponectin production in white adipose tissue. EP4 activation promoted ATM polarization toward the M2 phenotype in obese mice; accordingly, our <italic>in vitro</italic> experiments verified that EP4 signaling played a crucial role in the differentiation and polarization of murine peritoneal macrophages. Further investigation to clarify the detailed molecular mechanisms underlying the effects of EP4 signaling on macrophage differentiation and polarization in other insulin-target organs will provide new insights into the pathogenesis, as well as novel therapeutic targets, of obesity-related insulin resistance and T2DM.</p>
</sec>
<sec id="sec009" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec010">
<title>Ethics statement</title>
<p>All animal care and experiments were conducted following the guidelines for the Japan’s Act on Welfare and Management of Animals (Act No. 105 of October 1, 1973). These studies were approved by the Institutional Animal Care and Use Committees (IACUC)/ethics committee of Kyoto University (Permit Number: MedKyo15183). All sections of this report are based on the ARRIVE Guidelines for reporting animal research [<xref rid="pone.0136304.ref061" ref-type="bibr">61</xref>]. A completed ARRIVAL guidelines checklist is included in <xref rid="pone.0136304.s001" ref-type="supplementary-material">S1 Checklist</xref>. All surgery was performed when mice were anesthetized by 40 mg/kg of pentobarbital sodium (Kyoritsu Seiyaku, Tokyo, Japan); blood and tissue collection were performed as terminal procedures under anesthesia as described above, and all efforts were made to minimize suffering.</p>
</sec>
<sec id="sec011">
<title>Animals</title>
<p>Five-week-old male <italic>db/db</italic> mice were obtained from Oriental BioService (Kyoto, Japan). Homozygotic EP4-deficient mice and WT mice with the same genetic background were obtained by crossing mice heterozygous for the <italic>PTGER4</italic> mutation and were verified as previously described [<xref rid="pone.0136304.ref062" ref-type="bibr">62</xref>]. We used 26 <italic>db/db</italic> mice housed in groups of 2. Other varieties of mice had 6 mice per group and were housed in groups of 6. Mice were maintained in a specific pathogen-free facility (12 h light/dark cycles) and were fed normal chow <italic>ad libitum</italic> unless otherwise indicated.</p>
</sec>
<sec id="sec012">
<title>Treatment of db/db mice with EP4 receptor–selective agonist</title>
<p>ONO-AE1-329 (Ono Pharmaceutical, Osaka, Japan), an EP4-selective agonist [<xref rid="pone.0136304.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0136304.ref063" ref-type="bibr">63</xref>], was suspended in vehicle (0.3% ethanol and 0.1% Tween 80 in PBS), and 0.3 mg/kg of the reagent or vehicle was administrated subcutaneously to 7-week-old <italic>db/db</italic> mice twice a day for 4 weeks. We allocated animals into 2 groups as the vehicle–treated group and the ONO-AE1-329–treated group with 13 mice based on body weight (vehicle: 38.93 ± 0.62, ONO-AE1-329: 39.78 ± 0.52; mean ± SE, no significant difference) at the start of the experiment in order to minimize the effect of subjective bias.</p>
</sec>
<sec id="sec013">
<title>Glucose and insulin tolerance test</title>
<p>After an overnight fast, we administered 1.5 g/kg of D(+)-glucose (Wako Pure Chemical Industries, Osaka, Japan) and 0.75 U/kg of Humulin R (Eli Lilly Japan, Kobe, Japan) intraperitoneally to perform the glucose tolerance test (ipGTT) and the insulin tolerance test (ITT), respectively.</p>
</sec>
<sec id="sec014">
<title>Plasma variables</title>
<p>Plasma levels of blood glucose (BG), total cholesterol (T-Cho), triglyceride (TG), hemoglobin A1c (HbA1c), and adiponectin were measured using the Glucose CII Test Wako (Wako), the Total Cholesterol E-Test Wako (Wako), the Triglyceride E-Test Wako (Wako), the Glycohemoglobin A1c kit (Sanwa Kagaku Kenkyusho, Nagoya, Japan), and the Adiponectin ELISA kit (Otsuka Pharmaceutical, Tokyo, Japan), respectively.</p>
</sec>
<sec id="sec015">
<title>Histology</title>
<p>Epididymal adipose tissue was harvested and fixed overnight with 4% paraformaldehyde (Wako), embedded in paraffin, and sectioned. For H&amp;E staining, we stained the rehydrated sections using Mayer’s hematoxylin solution (Wako). For immunohistochemistry, the rehydrated sections were blocked with Protein Block Serum-Free (Dako, Glostrup, Denmark) and the macrophages were stained using rat monoclonal anti-F4/80 antibody (Abcam, Cambridge, MA, USA; clone CI:A3-1, 1:100; AB_1140040) and visualized by coloring with diaminobenzidine (DAB; Vector Laboratories, Burlingame, CA, USA). For immunofluorescence staining, blocked sections were incubated with a combination of rat anti-F4/80 antibody (Abcam; clone CI:A3-1, 1:100; AB_1140040) and either rabbit polyclonal anti-CD11c antibody (Santa Cruz Biotechnology, Dallas, TX, USA; clone M-50, 1:100; AB_2129774) or rabbit polyclonal anti-CD163 antibody (Santa Cruz Biotechnology; clone M-96, 1:100; AB_2074556). After washing, the sections were incubated with Alexa Fluor 488–conjugated donkey anti-rat antibody (Invitrogen, Carlsbad, CA, USA) or Alexa Fluor 594–conjugated donkey anti-rabbit antibody (Invitrogen). Non-immune rat IgG (Vector Laboratories) and rabbit IgG (Santa Cruz Biotechnology) served as negative controls for each experiment.</p>
</sec>
<sec id="sec016">
<title>Quantitative PCR</title>
<p>Total RNA was extracted from adipose tissue, stromal vascular fraction (SVF), and peritoneal macrophages using the RNeasy Lipid Tissue Mini kit (Qiagen, Valencia, CA, USA), RNeasy Micro kit (Qiagen), and RNeasy Mini kit (Qiagen), respectively. RNA was reverse-transcribed by High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Forster City, CA, USA). Samples were processed on the 7300 Real-Time PCR System (Applied Biosystems) using the Power SYBR Green PCR Master Mix (Applied Biosystems). All experiments were performed in duplicate, and results were normalized to <italic>β-actin</italic> expression level. The sequences of the sense and antisense primers used for amplification are as follows; <italic>β-actin</italic>: 5'-CCTGAGCGCAAGTACTCTGTGT-3’, 5'-GCTGATCCACATCTGCTGGAA-3’; <italic>Tnfα</italic>: 5'-CATCTTCTCAAAATTCGAGTGACAA-3’, 5'-TGGGAGTAGACAAGGTACAACCC-3’; <italic>Il-6</italic>: 5'-TAGTCCTTCCTACCCCAATTTCC-3’, 5'-TTGGTCCTTAGCCACTCCTTC-3’; <italic>Mcp-1</italic>: 5'-GCTGGAGCATCCACGTGTT-3’, 5'-ATCTTGCTGGTGAATGTGTAGCA-3’; <italic>IP-10</italic>: 5’-GCCGTCATTTTCTGCCTCAT-3’, 5’-GCTTCCCTATGGCCCTCATT-3’; <italic>Cd11c</italic>: 5'-CTGGATAGCCTTTCTTCTGCTG-3’, 5'-GCACACTGTGTCCGAACTC-3’; <italic>MR</italic>: 5'-GCTGAATCCCAGAAATTCCGC-3’, 5'-ATCACAGGCATACAGGGTGAC-3’; <italic>Cd163</italic>: 5'-GGGTCATTCAGAGGCACACTG-3’, 5'-CTGGCTGTCCTGTCAAGGCT-3’; <italic>Adiponectin</italic>: 5'- GATGGCAGAGATGGCACTCC-3’, 5'-CTTGCCAGTGCTGCCGTCAT-3’; <italic>PPARδ</italic>: 5'-AGATGGTGGCAGAGCTATGACC-3’, 5'-TCTCCTCCTGTGGCTGTTCC-3’; <italic>PPARγ</italic>: 5'-CTCCAAGAATACCAAAGTGCGA-3’, 5'-GCCTGATGCTTTATCCCCACA-3’; <italic>PPARα</italic>: 5'- ATGCCAGTACTGCCGTTTTC-3’, 5'-CCGAATCTTTCAGGTCGTGT-3’.</p>
</sec>
<sec id="sec017">
<title>Isolation of stromal vascular fraction (SVF)</title>
<p>Epididymal adipose tissues were minced and digested in 0.2% collagenase (Wako) in PBS for 2 h at 37°C. The digested tissues were passed through a 100 μm nylon mesh filter (BD Biosciences, San Jose, CA, USA) to remove the floating adipocytes, and the filtrates were spun for 5 min at 1,200 rpm. The pellet was incubated with Lysing Buffer (BD Biosciences) for 2 min to remove the red blood cells.</p>
</sec>
<sec id="sec018">
<title>In vitro M1/M2 polarization assay</title>
<p>Peritoneal macrophages were extracted from the peritoneal lavage of 12 to 15-week-old male EP4-deficient mice or WT mice with the same genetic background. The <italic>in vitro</italic> M1/M2 polarization assay was performed as previously described [<xref rid="pone.0136304.ref035" ref-type="bibr">35</xref>]. Briefly, together with 1 μM of ONO-AE1-329 or vehicle, peritoneal macrophages were treated with 1 μg/ml of LPS (<italic>Escherichia coli</italic> O55: B5, Calbiochem, La Jolla, CA, USA) or 20 ng/ml of IL-4 (R&amp;D Systems, Minneapolis, MN, USA) and IL-13 (R&amp;D Systems) for 8 h. Meanwhile, to explore the roles of PPARs in EP4-dependent M2 polarization, 0.1 μM of GSK3787 (Tocris Bioscience, Bristol, UK), selective antagonist for PPARδ, or 1 μM of GW9662 (Cayman Chemical, Ann Arbor, MI, USA), selective antagonist for PPARγ, was added into the medium 2h before IL-4/IL-13 and the EP4 agonist treatment.</p>
</sec>
<sec id="sec019">
<title>Cytometric bead assay</title>
<p>Epididymal WAT was homogenized in RIPA buffer (Wako) with Protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). MCP-1 concentration in the supernatants of epididymal WAT homogenates was measured using the BD CBA assay (BD Biosciences).</p>
</sec>
<sec id="sec020">
<title>Statistical analysis</title>
<p>Results are presented as the mean ± SEM. All data were analyzed with Kaleida Graph software (version4.1J; Synergy Software, Reading, PA, USA). Differences between two value sets were determined using the unpaired, two-tailed Student’s <italic>t</italic>-test. A one-way ANOVA followed by Turkey-Kramer analysis was used for testing the differences among three or more groups. Significance was defined as a p-value less than 0.05.</p>
</sec>
</sec>
<sec id="sec021">
<title>Supporting Information</title>
<supplementary-material id="pone.0136304.s001" xlink:href="info:doi/10.1371/journal.pone.0136304.s001" mimetype="application/pdf" position="float" xlink:type="simple">
<label>S1 Checklist</label>
<caption>
<title>Completed ARRIVE Guidelines Checklist for reporting animal data in this manuscript.</title>
<p>(PDF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0136304.s002" xlink:href="info:doi/10.1371/journal.pone.0136304.s002" mimetype="image/tiff" position="float" xlink:type="simple">
<label>S1 Fig</label>
<caption>
<title>Impact of EP4 activation on MCP-1 production in adipose tissue.</title>
<p>The relative mRNA levels (A) and the protein concentrations (B) of MCP-1 in epididymal adipose tissue were measured in <italic>db/db</italic> mice administered EP4 agonist (black bar) or vehicle (white bar). All values are mean ± SEM (A: n = 6 each, B: n = 6–8 each).</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0136304.s003" xlink:href="info:doi/10.1371/journal.pone.0136304.s003" mimetype="image/tiff" position="float" xlink:type="simple">
<label>S2 Fig</label>
<caption>
<title>EP4 activation enhances the gene expression levels of PPARs in adipose tissue.</title>
<p>Relative expression of <italic>PPARδ</italic>, <italic>PPARγ</italic>, and <italic>PPARα</italic> mRNA in epididymal adipose tissue from <italic>db/db</italic> mice administered EP4 agonist (black bar) or vehicle (white bar). All values are mean ± SEM (n = 4–5 each). ♯ p&lt;0.01 vs. vehicle. PPAR, peroxidase proliferator–activated receptor.</p>
<p>(TIF)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>Tomoyuki Furuyashiki and Shu Narumiya (Kyoto University, Kyoto, JAPAN) kindly provided EP4-mutated mice. We thank Ono Pharmaceutical for supplying the EP4 agonist ONO-AE1-329. We also thank Erina Tajima and Yoshiko Fujiwara for skillful technical assistance.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0136304.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faust</surname> <given-names>IM</given-names></name>, <name name-style="western"><surname>Johnson</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Stern</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Hirsch</surname> <given-names>J</given-names></name> (<year>1978</year>) <article-title>Diet-induced adipocyte number increase in adult rats: a new model of obesity</article-title>. <source>Am J Physiol</source> <volume>235</volume>: <fpage>E279</fpage>–<lpage>286</lpage>. <object-id pub-id-type="pmid">696822</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Barnes</surname> <given-names>GT</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Chou</surname> <given-names>CJ</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance</article-title>. <source>J Clin Invest</source> <volume>112</volume>: <fpage>1821</fpage>–<lpage>1830</lpage>. <object-id pub-id-type="pmid">14679177</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Olefsky</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Glass</surname> <given-names>CK</given-names></name> (<year>2010</year>) <article-title>Macrophages, inflammation, and insulin resistance</article-title>. <source>Annu Rev Physiol</source> <volume>72</volume>: <fpage>219</fpage>–<lpage>246</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1146/annurev-physiol-021909-135846" xlink:type="simple">10.1146/annurev-physiol-021909-135846</ext-link></comment> <object-id pub-id-type="pmid">20148674</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arkan</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Hevener</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Greten</surname> <given-names>FR</given-names></name>, <name name-style="western"><surname>Maeda</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>ZW</given-names></name>, <name name-style="western"><surname>Long</surname> <given-names>JM</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>IKK-beta links inflammation to obesity-induced insulin resistance</article-title>. <source>Nat Med</source> <volume>11</volume>: <fpage>191</fpage>–<lpage>198</lpage>. <object-id pub-id-type="pmid">15685170</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ueki</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kondo</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kahn</surname> <given-names>CR</given-names></name> (<year>2004</year>) <article-title>Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms</article-title>. <source>Mol Cell Biol</source> <volume>24</volume>: <fpage>5434</fpage>–<lpage>5446</lpage>. <object-id pub-id-type="pmid">15169905</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Osborn</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Olefsky</surname> <given-names>JM</given-names></name> (<year>2012</year>) <article-title>The cellular and signaling networks linking the immune system and metabolism in disease</article-title>. <source>Nat Med</source> <volume>18</volume>: <fpage>363</fpage>–<lpage>374</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nm.2627" xlink:type="simple">10.1038/nm.2627</ext-link></comment> <object-id pub-id-type="pmid">22395709</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mosser</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Edwards</surname> <given-names>JP</given-names></name> (<year>2008</year>) <article-title>Exploring the full spectrum of macrophage activation</article-title>. <source>Nat Rev Immunol</source> <volume>8</volume>: <fpage>958</fpage>–<lpage>969</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nri2448" xlink:type="simple">10.1038/nri2448</ext-link></comment> <object-id pub-id-type="pmid">19029990</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lumeng</surname> <given-names>CN</given-names></name>, <name name-style="western"><surname>Bodzin</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Saltiel</surname> <given-names>AR</given-names></name> (<year>2007</year>) <article-title>Obesity induces a phenotypic switch in adipose tissue macrophage polarization</article-title>. <source>J Clin Invest</source> <volume>117</volume>: <fpage>175</fpage>–<lpage>184</lpage>. <object-id pub-id-type="pmid">17200717</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ricciotti</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>FitzGerald</surname> <given-names>GA</given-names></name> (<year>2011</year>) <article-title>Prostaglandins and inflammation</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>31</volume>: <fpage>986</fpage>–<lpage>1000</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/ATVBAHA.110.207449" xlink:type="simple">10.1161/ATVBAHA.110.207449</ext-link></comment> <object-id pub-id-type="pmid">21508345</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Needleman</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Turk</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jakschik</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Morrison</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Lefkowith</surname> <given-names>JB</given-names></name> (<year>1986</year>) <article-title>Arachidonic acid metabolism</article-title>. <source>Annu Rev Biochem</source> <volume>55</volume>: <fpage>69</fpage>–<lpage>102</lpage>. <object-id pub-id-type="pmid">3017195</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Coleman</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>WL</given-names></name>, <name name-style="western"><surname>Narumiya</surname> <given-names>S</given-names></name> (<year>1994</year>) <article-title>International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes</article-title>. <source>Pharmacol Rev</source> <volume>46</volume>: <fpage>205</fpage>–<lpage>229</lpage>. <object-id pub-id-type="pmid">7938166</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takayama</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Sukhova</surname> <given-names>GK</given-names></name>, <name name-style="western"><surname>Chin</surname> <given-names>MT</given-names></name>, <name name-style="western"><surname>Libby</surname> <given-names>P</given-names></name> (<year>2006</year>) <article-title>A novel prostaglandin E receptor 4-associated protein participates in antiinflammatory signaling</article-title>. <source>Circ Res</source> <volume>98</volume>: <fpage>499</fpage>–<lpage>504</lpage>. <object-id pub-id-type="pmid">16424369</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Minami</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shimizu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Okamoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Folco</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ilasaca</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Feinberg</surname> <given-names>MW</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation</article-title>. <source>J Biol Chem</source> <volume>283</volume>: <fpage>9692</fpage>–<lpage>9703</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M709663200" xlink:type="simple">10.1074/jbc.M709663200</ext-link></comment> <object-id pub-id-type="pmid">18270204</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kabashima</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Saji</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Murata</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nagamachi</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Matsuoka</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Segi</surname> <given-names>E</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut</article-title>. <source>J Clin Invest</source> <volume>109</volume>: <fpage>883</fpage>–<lpage>893</lpage>. <object-id pub-id-type="pmid">11927615</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xiao</surname> <given-names>CY</given-names></name>, <name name-style="western"><surname>Yuhki</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hara</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Fujino</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kuriyama</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Yamada</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4</article-title>. <source>Circulation</source> <volume>109</volume>: <fpage>2462</fpage>–<lpage>2468</lpage>. <object-id pub-id-type="pmid">15123528</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tang</surname> <given-names>EH</given-names></name>, <name name-style="western"><surname>Shimizu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Christen</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Rocha</surname> <given-names>VZ</given-names></name>, <name name-style="western"><surname>Shvartz</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Tesmenitsky</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions</article-title>. <source>Cardiovasc Res</source> <volume>89</volume>: <fpage>234</fpage>–<lpage>243</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/cvq262" xlink:type="simple">10.1093/cvr/cvq262</ext-link></comment> <object-id pub-id-type="pmid">20736236</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ogawa</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kosuge</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Takayama</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Nagai</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Isobe</surname> <given-names>M</given-names></name> (<year>2009</year>) <article-title>The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation</article-title>. <source>Transplantation</source> <volume>87</volume>: <fpage>1645</fpage>–<lpage>1653</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/TP.0b013e3181a5c84c" xlink:type="simple">10.1097/TP.0b013e3181a5c84c</ext-link></comment> <object-id pub-id-type="pmid">19502955</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tang</surname> <given-names>EH</given-names></name>, <name name-style="western"><surname>Shvartz</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Shimizu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Rocha</surname> <given-names>VZ</given-names></name>, <name name-style="western"><surname>Zheng</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fukuda</surname> <given-names>D</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>31</volume>: <fpage>261</fpage>–<lpage>269</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/ATVBAHA.110.216580" xlink:type="simple">10.1161/ATVBAHA.110.216580</ext-link></comment> <object-id pub-id-type="pmid">21088251</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sugimoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tsuboi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Okuno</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Tamba</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tsuchiya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tsujimoto</surname> <given-names>G</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Microarray evaluation of EP4 receptor-mediated prostaglandin E2 suppression of 3T3-L1 adipocyte differentiation</article-title>. <source>Biochem Biophys Res Commun</source> <volume>322</volume>: <fpage>911</fpage>–<lpage>917</lpage>. <object-id pub-id-type="pmid">15336550</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vennemann</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Gerstner</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Kern</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Ferreiros Bouzas</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Narumiya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Maruyama</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>PTGS-2-PTGER2/4 signaling pathway partially protects from diabetogenic toxicity of streptozotocin in mice</article-title>. <source>Diabetes</source> <volume>61</volume>: <fpage>1879</fpage>–<lpage>1887</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db11-1396" xlink:type="simple">10.2337/db11-1396</ext-link></comment> <object-id pub-id-type="pmid">22522619</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yokota</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Meka</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Medina</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Igarashi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Comp</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2002</year>) <article-title>Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins</article-title>. <source>J Clin Invest</source> <volume>109</volume>: <fpage>1303</fpage>–<lpage>1310</lpage>. <object-id pub-id-type="pmid">12021245</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shibata</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Sato</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Pimentel</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Takemura</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Kihara</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ohashi</surname> <given-names>K</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms</article-title>. <source>Nat Med</source> <volume>11</volume>: <fpage>1096</fpage>–<lpage>1103</lpage>. <object-id pub-id-type="pmid">16155579</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Johansson</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Woodling</surname> <given-names>NS</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Montine</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Andreasson</surname> <given-names>K</given-names></name> (<year>2010</year>) <article-title>The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity</article-title>. <source>J Immunol</source> <volume>184</volume>: <fpage>7207</fpage>–<lpage>7218</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4049/jimmunol.0903487" xlink:type="simple">10.4049/jimmunol.0903487</ext-link></comment> <object-id pub-id-type="pmid">20483760</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Woodling</surname> <given-names>NS</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Anacker</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pan</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Signaling via the prostaglandin E(2) receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia</article-title>. <source>J Clin Invest</source> <volume>121</volume>: <fpage>4362</fpage>–<lpage>4371</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1172/JCI46279" xlink:type="simple">10.1172/JCI46279</ext-link></comment> <object-id pub-id-type="pmid">21965326</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weisberg</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>McCann</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Desai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rosenbaum</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Leibel</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Ferrante</surname> <given-names>AW</given-names> <suffix>Jr</suffix></name>. (<year>2003</year>) <article-title>Obesity is associated with macrophage accumulation in adipose tissue</article-title>. <source>J Clin Invest</source> <volume>112</volume>: <fpage>1796</fpage>–<lpage>1808</lpage>. <object-id pub-id-type="pmid">14679176</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Odegaard</surname> <given-names>JI</given-names></name>, <name name-style="western"><surname>Ricardo-Gonzalez</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Goforth</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Morel</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Subramanian</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Mukundan</surname> <given-names>L</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance</article-title>. <source>Nature</source> <volume>447</volume>: <fpage>1116</fpage>–<lpage>1120</lpage>. <object-id pub-id-type="pmid">17515919</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Reilly</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Karabacak</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Gangl</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hatano</surname> <given-names>B</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity</article-title>. <source>Cell Metab</source> <volume>7</volume>: <fpage>485</fpage>–<lpage>495</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2008.04.002" xlink:type="simple">10.1016/j.cmet.2008.04.002</ext-link></comment> <object-id pub-id-type="pmid">18522830</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Odegaard</surname> <given-names>JI</given-names></name>, <name name-style="western"><surname>Ricardo-Gonzalez</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Red</surname> <given-names>Eagle A</given-names></name>, <name name-style="western"><surname>Vats</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Morel</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Goforth</surname> <given-names>MH</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance</article-title>. <source>Cell Metab</source> <volume>7</volume>: <fpage>496</fpage>–<lpage>507</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2008.04.003" xlink:type="simple">10.1016/j.cmet.2008.04.003</ext-link></comment> <object-id pub-id-type="pmid">18522831</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stienstra</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Duval</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Keshtkar</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>van der Laak</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kersten</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Müller</surname> <given-names>M</given-names></name> (<year>2008</year>) <article-title>Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue</article-title>. <source>J Biol Chem</source> <volume>283</volume>: <fpage>22620</fpage>–<lpage>22627</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M710314200" xlink:type="simple">10.1074/jbc.M710314200</ext-link></comment> <object-id pub-id-type="pmid">18541527</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Piya</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>McTernan</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>S</given-names></name> (<year>2013</year>) <article-title>Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin</article-title>. <source>J Endocrinol</source> <volume>216</volume>: <fpage>T1</fpage>–<lpage>T15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1530/JOE-12-0498" xlink:type="simple">10.1530/JOE-12-0498</ext-link></comment> <object-id pub-id-type="pmid">23160966</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hiuge</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Tenenbaum</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Maeda</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Benderly</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Kumada</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fisman</surname> <given-names>EZ</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <volume>27</volume>: <fpage>635</fpage>–<lpage>641</lpage>. <object-id pub-id-type="pmid">17194889</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iwaki</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Matsuda</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Maeda</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Funahashi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Matsuzawa</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Makishima</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors</article-title>. <source>Diabetes</source> <volume>52</volume>: <fpage>1655</fpage>–<lpage>1663</lpage>. <object-id pub-id-type="pmid">12829629</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>van de Wall</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Laplante</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Azzara</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Trujillo</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Hofmann</surname> <given-names>SM</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Obesity-associated improvements in metabolic profile through expansion of adipose tissue</article-title>. <source>J Clin Invest</source> <volume>117</volume>: <fpage>2621</fpage>–<lpage>2637</lpage>. <object-id pub-id-type="pmid">17717599</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lovren</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Pan</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Quan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Szmitko</surname> <given-names>PE</given-names></name>, <name name-style="western"><surname>Singh</surname> <given-names>KK</given-names></name>, <name name-style="western"><surname>Shukla</surname> <given-names>PC</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <volume>299</volume>: <fpage>H656</fpage>–<lpage>663</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpheart.00115.2010" xlink:type="simple">10.1152/ajpheart.00115.2010</ext-link></comment> <object-id pub-id-type="pmid">20622108</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nakanishi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Nakatsuji</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Seno</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ishizu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Akitake-Kawano</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kanda</surname> <given-names>K</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps</article-title>. <source>Carcinogenesis</source> <volume>32</volume>: <fpage>1333</fpage>–<lpage>1339</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/carcin/bgr128" xlink:type="simple">10.1093/carcin/bgr128</ext-link></comment> <object-id pub-id-type="pmid">21730361</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fain</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Leffler</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Bahouth</surname> <given-names>SW</given-names></name> (<year>2000</year>) <article-title>Eicosanoids as endogenous regulators of leptin release and lipolysis by mouse adipose tissue in primary culture</article-title>. <source>J Lipid Res</source> <volume>41</volume>: <fpage>1689</fpage>–<lpage>1694</lpage>. <object-id pub-id-type="pmid">11013312</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fain</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Leffler</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Bahouth</surname> <given-names>SW</given-names></name>, <name name-style="western"><surname>Rice</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Rivkees</surname> <given-names>SA</given-names></name> (<year>2000</year>) <article-title>Regulation of leptin release and lipolysis by PGE2 in rat adipose tissue</article-title>. <source>Prostaglandins Other Lipid Mediat</source> <volume>62</volume>: <fpage>343</fpage>–<lpage>350</lpage>. <object-id pub-id-type="pmid">11060898</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fain</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Leffler</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Cowan</surname> <given-names>GS</given-names> <suffix>Jr</suffix></name>, <name name-style="western"><surname>Buffington</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Pouncey</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Bahouth</surname> <given-names>SW</given-names></name> (<year>2001</year>) <article-title>Stimulation of leptin release by arachidonic acid and prostaglandin E(2) in adipose tissue from obese humans</article-title>. <source>Metabolism</source> <volume>50</volume>: <fpage>921</fpage>–<lpage>928</lpage>. <object-id pub-id-type="pmid">11474480</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sanchez-Alavez</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Klein</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Brownell</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Tabarean</surname> <given-names>IV</given-names></name>, <name name-style="western"><surname>Davis</surname> <given-names>CN</given-names></name>, <name name-style="western"><surname>Conti</surname> <given-names>B</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Night eating and obesity in the EP3R-deficient mouse</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>104</volume>: <fpage>3009</fpage>–<lpage>3014</lpage>. <object-id pub-id-type="pmid">17307874</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ohinata</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Suetsugu</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Fujiwara</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yoshikawa</surname> <given-names>M</given-names></name> (<year>2006</year>) <article-title>Activation of prostaglandin E receptor EP4 subtype suppresses food intake in mice</article-title>. <source>Prostaglandins Other Lipid Mediat</source> <volume>81</volume>: <fpage>31</fpage>–<lpage>36</lpage>. <object-id pub-id-type="pmid">16997129</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hishikari</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ogawa</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Isobe</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Takahashi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Onishi</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury</article-title>. <source>Cardiovasc Res</source> <volume>81</volume>: <fpage>123</fpage>–<lpage>132</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cvr/cvn254" xlink:type="simple">10.1093/cvr/cvn254</ext-link></comment> <object-id pub-id-type="pmid">18805784</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chawla</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Goh</surname> <given-names>YP</given-names></name> (<year>2011</year>) <article-title>Macrophage-mediated inflammation in metabolic disease</article-title>. <source>Nat Rev Immunol</source> <volume>11</volume>: <fpage>738</fpage>–<lpage>749</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nri3071" xlink:type="simple">10.1038/nri3071</ext-link></comment> <object-id pub-id-type="pmid">21984069</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Largo</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Diez-Ortego</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Sanchez-Pernaute</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Lopez-Armada</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Alvarez-Soria</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Egido</surname> <given-names>J</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>EP2/EP4 signalling inhibits monocyte chemoattractant protein-1 production induced by interleukin 1beta in synovial fibroblasts</article-title>. <source>Ann Rheum Dis</source> <volume>63</volume>: <fpage>1197</fpage>–<lpage>1204</lpage>. <object-id pub-id-type="pmid">15361371</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zahner</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schaper</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Panzer</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Kluger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Stahl</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Thaiss</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Prostaglandin EP2 and EP4 receptors modulate expression of the chemokine CCL2 (MCP-1) in response to LPS-induced renal glomerular inflammation</article-title>. <source>Biochem J</source> <volume>422</volume>: <fpage>563</fpage>–<lpage>570</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1042/BJ20090420" xlink:type="simple">10.1042/BJ20090420</ext-link></comment> <object-id pub-id-type="pmid">19570035</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Satoh</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kidoya</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Naito</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Yamamoto</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Takemura</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Nakagawa</surname> <given-names>K</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages</article-title>. <source>Nature</source> <volume>495</volume>: <fpage>524</fpage>–<lpage>528</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature11930" xlink:type="simple">10.1038/nature11930</ext-link></comment> <object-id pub-id-type="pmid">23515163</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Saraswathi</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Ramnanan</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Wilks</surname> <given-names>AW</given-names></name>, <name name-style="western"><surname>Desouza</surname> <given-names>CV</given-names></name>, <name name-style="western"><surname>Eller</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Murali</surname> <given-names>G</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Impact of hematopoietic cyclooxygenase-1 deficiency on obesity-linked adipose tissue inflammation and metabolic disorders in mice</article-title>. <source>Metabolism</source> <volume>62</volume>: <fpage>1673</fpage>–<lpage>1685</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.metabol.2013.07.007" xlink:type="simple">10.1016/j.metabol.2013.07.007</ext-link></comment> <object-id pub-id-type="pmid">23987235</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brestoff</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Artis</surname> <given-names>D</given-names></name> (<year>2015</year>) <article-title>Immune regulation of metabolic homeostasis in health and disease</article-title>. <source>Cell</source> <volume>161</volume>: <fpage>146</fpage>–<lpage>160</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2015.02.022" xlink:type="simple">10.1016/j.cell.2015.02.022</ext-link></comment> <object-id pub-id-type="pmid">25815992</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hill</surname> <given-names>AA</given-names></name>, <name name-style="western"><surname>Reid</surname> <given-names>Bolus W</given-names></name>, <name name-style="western"><surname>Hasty</surname> <given-names>AH</given-names></name> (<year>2014</year>) <article-title>A decade of progress in adipose tissue macrophage biology</article-title>. <source>Immunol Rev</source> <volume>262</volume>: <fpage>134</fpage>–<lpage>152</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/imr.12216" xlink:type="simple">10.1111/imr.12216</ext-link></comment> <object-id pub-id-type="pmid">25319332</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Orr</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Kennedy</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Anderson-Baucum</surname> <given-names>EK</given-names></name>, <name name-style="western"><surname>Webb</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Fordahl</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Erikson</surname> <given-names>KM</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>Obesity alters adipose tissue macrophage iron content and tissue iron distribution</article-title>. <source>Diabetes</source> <volume>63</volume>: <fpage>421</fpage>–<lpage>432</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db13-0213" xlink:type="simple">10.2337/db13-0213</ext-link></comment> <object-id pub-id-type="pmid">24130337</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>YW</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>McCrady-Spitzer</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Levine</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Wei</surname> <given-names>LN</given-names></name> (<year>2014</year>) <article-title>Reducing RIP140 expression in macrophage alters ATM infiltration, facilitates white adipose tissue browning, and prevents high-fat diet-induced insulin resistance</article-title>. <source>Diabetes</source> <volume>63</volume>: <fpage>4021</fpage>–<lpage>4031</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2337/db14-0619" xlink:type="simple">10.2337/db14-0619</ext-link></comment> <object-id pub-id-type="pmid">24969109</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nguyen</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Qiu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Cui</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Goh</surname> <given-names>YP</given-names></name>, <name name-style="western"><surname>Mwangi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>David</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis</article-title>. <source>Nature</source> <volume>480</volume>: <fpage>104</fpage>–<lpage>108</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature10653" xlink:type="simple">10.1038/nature10653</ext-link></comment> <object-id pub-id-type="pmid">22101429</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ouchi</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Parker</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Lugus</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Walsh</surname> <given-names>K</given-names></name> (<year>2011</year>) <article-title>Adipokines in inflammation and metabolic disease</article-title>. <source>Nat Rev Immunol</source> <volume>11</volume>: <fpage>85</fpage>–<lpage>97</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nri2921" xlink:type="simple">10.1038/nri2921</ext-link></comment> <object-id pub-id-type="pmid">21252989</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fukushima</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kamada</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Matsumoto</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Yoshida</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ezaki</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Takemura</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Adiponectin prevents progression of steatohepatitis in mice by regulating oxidative stress and Kupffer cell phenotype polarization</article-title>. <source>Hepatol Res</source> <volume>39</volume>: <fpage>724</fpage>–<lpage>738</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1872-034X.2009.00509.x" xlink:type="simple">10.1111/j.1872-034X.2009.00509.x</ext-link></comment> <object-id pub-id-type="pmid">19473437</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pajvani</surname> <given-names>UB</given-names></name>, <name name-style="western"><surname>Hawkins</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Combs</surname> <given-names>TP</given-names></name>, <name name-style="western"><surname>Rajala</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Doebber</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Berger</surname> <given-names>JP</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity</article-title>. <source>J Biol Chem</source> <volume>279</volume>: <fpage>12152</fpage>–<lpage>12162</lpage>. <object-id pub-id-type="pmid">14699128</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Leary</surname> <given-names>VB</given-names></name>, <name name-style="western"><surname>Jorett</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Marchetti</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Gonzalez</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Phillips</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Ciaraldi</surname> <given-names>TP</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults</article-title>. <source>Am J Physiol Endocrinol Metab</source> <volume>293</volume>: <fpage>E421</fpage>–<lpage>427</lpage>. <object-id pub-id-type="pmid">17488807</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Regan</surname> <given-names>JW</given-names></name> (<year>2003</year>) <article-title>EP2 and EP4 prostanoid receptor signaling</article-title>. <source>Life Sci</source> <volume>74</volume>: <fpage>143</fpage>–<lpage>153</lpage>. <object-id pub-id-type="pmid">14607241</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref057"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Otani</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mizokami</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Hayashi</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Mori</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Nakamura</surname> <given-names>S</given-names></name>, <etal>et al</etal>. (<year>2015</year>) <article-title>Signaling pathway for adiponectin expression in adipocytes by osteocalcin</article-title>. <source>Cell Signal</source>.</mixed-citation></ref>
<ref id="pone.0136304.ref058"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Charo</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Holla</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Arumugam</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hwang</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dubois</surname> <given-names>RN</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor</article-title>. <source>Pancreas</source> <volume>42</volume>: <fpage>467</fpage>–<lpage>474</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MPA.0b013e318264d0f8" xlink:type="simple">10.1097/MPA.0b013e318264d0f8</ext-link></comment> <object-id pub-id-type="pmid">23090667</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref059"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Papadimitriou</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>King</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Persaud</surname> <given-names>SJ</given-names></name> (<year>2007</year>) <article-title>Anti-apoptotic effects of arachidonic acid and prostaglandin E2 in pancreatic beta-cells</article-title>. <source>Cell Physiol Biochem</source> <volume>20</volume>: <fpage>607</fpage>–<lpage>616</lpage>. <object-id pub-id-type="pmid">17762187</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref060"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Varma</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Yao-Borengasser</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rasouli</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Nolen</surname> <given-names>GT</given-names></name>, <name name-style="western"><surname>Phanavanh</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Starks</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action</article-title>. <source>Am J Physiol Endocrinol Metab</source> <volume>296</volume>: <fpage>E1300</fpage>–<lpage>1310</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpendo.90885.2008" xlink:type="simple">10.1152/ajpendo.90885.2008</ext-link></comment> <object-id pub-id-type="pmid">19336660</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref061"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kilkenny</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Browne</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Cuthill</surname> <given-names>IC</given-names></name>, <name name-style="western"><surname>Emerson</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name> (<year>2010</year>) <article-title>Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research</article-title>. <source>PLoS Biol</source> <volume>8</volume>: <fpage>e1000412</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pbio.1000412" xlink:type="simple">10.1371/journal.pbio.1000412</ext-link></comment> <object-id pub-id-type="pmid">20613859</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref062"><label>62</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Segi</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Sugimoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yamasaki</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Aze</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Oida</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Nishimura</surname> <given-names>T</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice</article-title>. <source>Biochem Biophys Res Commun</source> <volume>246</volume>: <fpage>7</fpage>–<lpage>12</lpage>. <object-id pub-id-type="pmid">9600059</object-id></mixed-citation></ref>
<ref id="pone.0136304.ref063"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Suzawa</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Miyaura</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Inada</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Maruyama</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Sugimoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ushikubi</surname> <given-names>F</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs</article-title>. <source>Endocrinology</source> <volume>141</volume>: <fpage>1554</fpage>–<lpage>1559</lpage>. <object-id pub-id-type="pmid">10746663</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>